Success Metrics

Clinical Success Rate
87.1%

Based on 27 completed trials

Completion Rate
87%(27/31)
Active Trials
0(0%)
Results Posted
78%(21 trials)
Terminated
4(13%)

Phase Distribution

Ph phase_2
4
13%
Ph phase_3
18
58%
Ph phase_4
9
29%

Phase Distribution

0

Early Stage

4

Mid Stage

27

Late Stage

Phase Distribution31 total trials
Phase 2Efficacy & side effects
4(12.9%)
Phase 3Large-scale testing
18(58.1%)
Phase 4Post-market surveillance
9(29.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.1%

27 of 31 finished

Non-Completion Rate

12.9%

4 ended early

Currently Active

0

trials recruiting

Total Trials

31

all time

Status Distribution
Completed(27)
Terminated(4)

Detailed Status

Completed27
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
31
Active
0
Success Rate
87.1%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (12.9%)
Phase 318 (58.1%)
Phase 49 (29.0%)

Trials by Status

completed2787%
terminated413%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT00560404Phase 3

A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Completed
NCT00661388Phase 3

A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.

Completed
NCT01191983Phase 4

A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy

Completed
NCT00048048Phase 2

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Completed
NCT00737464Phase 4

A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Completed
NCT01066000Phase 4

A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia

Terminated
NCT00922116Phase 4

A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis

Completed
NCT01342640Phase 4

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Completed
NCT00394953Phase 3

A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

Completed
NCT00048035Phase 2

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Completed
NCT00364832Phase 2

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Completed
NCT00576602Phase 4

A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

Terminated
NCT00081484Phase 3

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Completed
NCT00081471Phase 3

A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Completed
NCT00077597Phase 3

A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Completed
NCT00442793Phase 3

A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Completed
NCT00773331Phase 3

A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.

Completed
NCT00922610Phase 4

A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients

Completed
NCT00077766Phase 3

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Completed
NCT00882713Phase 3

A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
31